Identification of Pathogenic Immune Cell Subsets in Checkpoint Inhibitor-induced Myocarditis

Published: 17 January 2022| Version 2 | DOI: 10.17632/cm8pxdt5pm.2
Han Zhu


Immune checkpoint inhibitors (ICIs) are monoclonal antibodies used widely to activate the immune system against tumor cells. Despite their therapeutic benefits, ICIs are known to cause immune-related adverse events (irAE) such as myocarditis, a rare but serious side effect with up to 50% mortality. To identify pathogenic immune subset(s) responsible for ICI myocarditis and other irAE, we performed single cell mass cytometry (CyTOF) on peripheral blood mononuclear cells from patients and controls with irAE including four patients with ICI myocarditis.


Steps to reproduce

Human PBMCs were collected and isolated from three main patient groups: Group A - patients on immune checkpoint inhibitors without any known immune adverse events (irAEs), Group B - patients on immune checkpoint inhibitors with non-myocarditis irAEs, Group C - patients on immune checkpoint inhibitors with myocarditis. CyTOF (mass cytometry) data was obtained on samples.


Flow Cytometry